Literature DB >> 33452292

Assessment of planning reproducibility in three-dimensional field-in-field radiotherapy technique for breast cancer: impact of surgery-simulation interval.

Dong Soo Lee1, Young Kyu Lee2,3, Young Nam Kang2, Yong Gyun Won2,4, Seung Hwan Park2, Yong Seok Kim5, Jeong Soo Kim5, Hye Sung Won6.   

Abstract

The three-dimensional field-in-field (3-D FIF) technique for radiotherapy is an advanced, state-of-the-art method that uses multileaf collimators to generate a homogeneous and conformal dose distribution via segmental subfields. The purpose of this study is to evaluate the dosimetric reproducibility of 3-D FIF plans using the original simulation computed tomography (iCT) scans and re-simulation CT (rCT) scans for whole breast irradiation (WBI) schedule. This study enrolled a total of 34 patients. The study population underwent iCT scans for standard WBI and took rCT scans after 45 Gy of WBI for cone down boost plans. The dosimetric parameters (V105%, V103%, V100%, V98%, V95%, V90%, V50%), plan quality indices (conformity index, homogeneity index) and clinical parameters (isocenter-breast axis, isocenter-lung axis, soft tissue volumes within radiation field, lung volumes within radiation field) were assessed. The median time interval from surgery to iCT was 33 days and from iCT to rCT was 35 days. All dosimetric parameters exhibited statistically significant differences between iCT and rCT among cohorts with a surgery-iCT interval of < 60 days. Homogeneity index showed a statistically significant increase from iCT to rCT among all cohorts. Soft tissue volumes (p = 0.001) and isocenter-breast axis (p = 0.032) exhibited statistically significant differences among cohorts with surgery-iCT interval < 60 days. Regarding the reproducibility of the 3-D FIF WBI plans, significant changes were observed in dosimetric and clinical factors, particularly in study cohorts with a surgery-simulation interval < 60 days. The main contributing factor of these transitions seemed to be the changes in volume of the soft tissue within the WBI field. Further confirmative studies are necessary to determine the most suitable timing and technique for WBI.

Entities:  

Year:  2021        PMID: 33452292      PMCID: PMC7810888          DOI: 10.1038/s41598-020-78666-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  34 in total

1.  A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.

Authors:  Giorgio Arcangeli; Paola Pinnarò; Rita Rambone; Diana Giannarelli; Marcello Benassi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-13       Impact factor: 7.038

2.  Hybrid IMRT plans--concurrently treating conventional and IMRT beams for improved breast irradiation and reduced planning time.

Authors:  Charles S Mayo; Marcia M Urie; Thomas J Fitzgerald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

3.  Evaluation of a commercial biologically based IMRT treatment planning system.

Authors:  Vladimir A Semenenko; Bodo Reitz; Ellen Day; X Sharon Qi; Moyed Miften; X Allen Li
Journal:  Med Phys       Date:  2008-12       Impact factor: 4.071

4.  Comparative evaluation of autocontouring in clinical practice: A practical method using the Turing test.

Authors:  Mark J Gooding; Annamarie J Smith; Maira Tariq; Paul Aljabar; Devis Peressutti; Judith van der Stoep; Bart Reymen; Daisy Emans; Djoya Hattu; Judith van Loon; Maud de Rooy; Rinus Wanders; Stephanie Peeters; Tim Lustberg; Johan van Soest; Andre Dekker; Wouter van Elmpt
Journal:  Med Phys       Date:  2018-10-12       Impact factor: 4.071

Review 5.  A review of setup error in supine breast radiotherapy using cone-beam computed tomography.

Authors:  Vikneswary Batumalai; Lois Holloway; Geoff P Delaney
Journal:  Med Dosim       Date:  2016-06-14       Impact factor: 1.482

6.  Intrafraction variability and deformation quantification in the breast.

Authors:  Carri K Glide-Hurst; Mira M Shah; Ryan G Price; Chang Liu; Jinkoo Kim; Meredith Mahan; Correen Fraser; Indrin J Chetty; Ibrahim Aref; Benjamin Movsas; Eleanor M Walker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-30       Impact factor: 7.038

7.  Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.

Authors:  Jennifer R Bellon; Steven E Come; Rebecca S Gelman; I Craig Henderson; Lawrence N Shulman; Barbara J Silver; Jay R Harris; Abram Recht
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

8.  The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.

Authors:  P M Poortmans; L Collette; H Bartelink; H Struikmans; W F Van den Bogaert; A Fourquet; J J Jager; W Hoogenraad; R-P Müller; J-B Dubois; M Bolla; M Van Der Hulst; C C Wárlám-Rodenhuis; M Pierart; J-C Horiot
Journal:  Cancer Radiother       Date:  2008-08-28       Impact factor: 1.018

9.  Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.

Authors:  Philip M Poortmans; Laurence Collette; Jean-Claude Horiot; Walter F Van den Bogaert; Alain Fourquet; Abraham Kuten; Evert M Noordijk; Willem Hoogenraad; René-Olivier Mirimanoff; Marianne Pierart; Erik Van Limbergen; Harry Bartelink
Journal:  Radiother Oncol       Date:  2008-08-15       Impact factor: 6.280

10.  Breast-conserving radiotherapy with simultaneous integrated boost; field-in-field three-dimensional conformal radiotherapy versus inverse intensity-modulated radiotherapy - A dosimetric comparison: Do we need intensity-modulated radiotherapy?

Authors:  Bindhu Joseph; Nisma Farooq; Sabari Kumar; C R Vijay; Kurian J Puthur; C Ramesh; Vishwanath Lokesh
Journal:  South Asian J Cancer       Date:  2018 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.